Table 4.
Pharmacokinetic parameters obtained for the administration of free and nanoencapsulated bevacizumab at 15 mg/kg. Data are expressed as mean ± SD (n = 6). Bevacizumab bevacizumab aqueous solution, B-NP-P bevacizumab-loaded nanoparticles coated with PEG35, B-DS-NP-P albumin nanoparticles containing the bevacizumab-DS complex coated with PEG35, po per oral, Tmax time to reach maximum plasma concentration, Cmax maximum plasma concentration, t1/2 half-life, AUC area under the curve, Fr relative oral bioavailability, NA not available
| tmax (days) | Cmax (μg/mL) | t1/2 (days) | AUC0-30d (μg/mL·d) | Fr | |
|---|---|---|---|---|---|
| Bevacizumab iv | 0 | 129 ± 1 | 13 ± 3 | 659 ± 31 | 100 |
| Bevacizumab po | NA | NA | NA | NA | NA |
| B-NP-P | 0.33 ± 0.05 | 0.08 ± 0.02 | NA | 0.06 ± 0.02 | 0.003 |
| B-DS-NP-P | 0.25 ± 0.08 | 10 ± 1 | 36 ± 14 | 73 ± 7 | 3.7 |